GeoVax Labs Faces Nasdaq Deficiency Over Stock Price

GeoVax Labs received a Nasdaq deficiency letter due to its stock's closing bid price being below $1.00 for 30 consecutive business days. The company has until January 27, 2026, to regain compliance, or it may qualify for an additional 180-day period or face potential delisting. The notification does not immediately affect GeoVax's Nasdaq listing, and the company plans to monitor its stock price and consider options to meet the requirement.

GeoVax Labs, Inc. (NASDAQ: GOVX), a biotechnology company specializing in vaccine and cancer therapy advancements, recently received a notice from the Nasdaq Stock Market due to its stock's closing bid price falling below the minimum requirement for continued listing. The company has been granted an initial compliance period of 180 calendar days, until January 27, 2026, to meet the minimum bid price requirement of $1.00 per share [1].

According to the Nasdaq listing rule 5550(a)(2), GeoVax's common stock must maintain a closing bid price of at least $1.00 for 30 consecutive business days to remain listed on the Nasdaq Capital Market. The company has been experiencing significant volatility, with its stock currently trading at $0.72 [1].

GeoVax Labs has stated that the notification does not immediately affect its Nasdaq listing, and the company plans to monitor its stock price and consider available options to regain compliance. If the closing bid price reaches at least $1.00 for a minimum of 10 consecutive business days before the deadline, Nasdaq staff will provide written confirmation that the company has regained compliance. If the company fails to meet this requirement, it may be eligible for an additional 180-day period, subject to meeting all other listing standards except for the bid price requirement [1].

The company's current market capitalization stands at $18.3 million, and it has been facing challenges due to its overall WEAK financial health score according to InvestingPro [1]. Despite these challenges, GeoVax Labs reported a significant increase in revenue during its Q2 2025 earnings call, with six-month revenues surging to $2.5 million, a notable rise from $301,000 in the same period last year [2].

GeoVax Labs is also calling for urgent investment in domestic manufacturing and vaccine diversification to address the global spread of Mpox and immune-evasive COVID variants. The company has renewed its call for decisive U.S. action on pandemic preparedness and biodefense, emphasizing the need to modernize the nation's countermeasure infrastructure and end foreign vaccine dependency [2].

References:
[1] https://www.investing.com/news/sec-filings/geovax-labs-receives-nasdaq-notice-for-noncompliance-with-minimum-bid-price-93CH-4166726
[2] https://finance.yahoo.com/news/geovax-urges-immediate-action-pandemic-130000451.html